{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Appendix 3: Contraceptive Guidance and Pregnancy Testing', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal unless', 'permanently sterile (see below)', 'Women in the following categories are not considered WOCBP:', 'Premenarchal', 'Premenopausal female with 1 of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's review of the participant's\", 'medical records, medical examination, or medical history interview.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an alternative', 'medical cause.', 'A high follicle stimulating hormone (FSH) level in the postmenopausal range may', 'be used to confirm a postmenopausal state in women not using hormonal', 'contraception or hormonal replacement therapy (HRT). However, in the absence', 'of 12 months of amenorrhea, confirmation with two FSH measurements in the', 'postmenopausal range is required.', 'Females on HRT and whose menopausal status is in doubt will be required to use', 'one of the non-hormonal highly effective contraception methods if they wish to', 'continue their HRT during the study. Otherwise, they must discontinue HRT to allow', 'confirmation of postmenopausal status before study enrolment.', 'For this study, male participants will be considered to be of non-reproductive potential if they', 'have azoospermia (whether due to having had a vasectomy or due to an underlying medical', 'condition).', 'Contraception Requirements', 'Female Participants:', 'Female participants of childbearing potential are eligible to participate if they agree to use a', 'highly effective method of contraception consistently and correctly as described in the table', 'below during the treatment period and for at least 180 days after the last administration of', 'study drug.', 'Male Participants:', 'Male participants with female partners of childbearing potential are eligible to participate if they', 'agree to use highly effective methods of contraception consistently during the treatment period', 'and for at least 180 days after the last administration of study drug (i.e. mandatory condom', 'use, mandatory use of effective methods of contraception for female partners of males', 'Confidential', 'Page 75 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'participating in the study as described in the table below, refrain from sperm donation for male', 'participants during the treatment period and for at least 180 days after the last administration', 'of study drug).', 'Highly Effective Contraception Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of < 1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing) hormonal contraception', 'b, C', 'Oral', 'Intravaginal', 'Transdermal', 'Injectable', 'Progestogen-only hormonal contraception', 'b, C', 'Oral', 'Injectable', 'Highly Effective Methods That Have Low User Dependency', 'Failure rate of < 1% per year when used consistently and correctly.', 'Progestogen- only contraceptive implant', 'b,', 'C', 'Intrauterine hormone-releasing system (IUS) b', 'Intrauterine device (IUD)', 'Bilateral tubal occlusion', 'Vasectomized partner', 'A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed.', 'If not, an additional highly effective method of contraception should be used.', 'Sexual abstinence', 'Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study intervention.', 'The reliability of sexual abstinence needs to be evaluated in relation to the duration of the', 'study and the preferred and usual lifestyle of the participant.)', 'Notes:', 'Use should be consistent with local regulations regarding the use of contraceptive methods', 'for participants of clinical studies.', 'a) Typical use failure rates are lower than perfect-use failure rates (i.e. when used consistently', 'and correctly).', 'b) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines,', 'acceptable hormonal contraceptives are limited to those which inhibit ovulation.', 'Confidential', 'Page 76 of 79']\n\n###\n\n", "completion": "END"}